Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.80 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29457342 | 1.00 | NAMPT (0.80) | NAMPTRAB9ANPC1PKMLMNA | |
| SCHEMBL6260359 | 0.92 | NAMPT (0.69) | NAMPTRAB9ANPC1PKMLMNA | |
| Ethoxycarbonyl Group SCHEMBL27838433 | 0.87 | NAMPT (0.63) | NAMPTRAB9ANPC1PKMLMNA | |
| SCHEMBL30737600 | 0.85 | NPC1 (0.61) | NAMPTRAB9ANPC1PKMLMNA | |
| SCHEMBL28088112 | 0.85 | NPC1 (0.61) | NAMPTRAB9ANPC1PKMLMNA | |
| SCHEMBL27556272 | 0.85 | NAMPT (0.61) | NAMPTRAB9ANPC1PKMLMNA | |
| SCHEMBL6756707 | 0.84 | NAMPT (0.60) | NAMPTRAB9AHTTCYP1A2 | |
| SCHEMBL6436602 | 0.84 | NAMPT (0.60) | NAMPTRAB9ANPC1PKMLMNA | |
| SCHEMBL6164499 | 0.84 | NAMPT (0.67) | NAMPTRAB9A | |
| SCHEMBL30352289 | 0.83 | KDM4E (0.62) | NAMPTRAB9ANPC1PKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930448-A | Chiral precisely regulated synthesis process of 2,2' - [ [ (1S, 2S) -1,2- (-) ] -bis [6- (1, 1- (-) ] phenol | 雅本化学股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119751277-A | Synthesis process of high-purity 2,2' - [ [ (1S, 2S) -1,2- (-) ] -bis [6- (1, 1- (-) ] phenol | 雅本化学股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-118496624-A | Resin composition and use thereof | 华为技术有限公司 | 2024-08-16 | — | — | CN | claimed |
| CN-102307622-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2012-01-04 | — | — | CN | claimed |
| CN-119930448-A | Chiral precisely regulated synthesis process of 2,2' - [ [ (1S, 2S) -1,2- (-) ] -bis [6- (1, 1- (-) ] phenol | 雅本化学股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119751277-A | Synthesis process of high-purity 2,2' - [ [ (1S, 2S) -1,2- (-) ] -bis [6- (1, 1- (-) ] phenol | 雅本化学股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-118496624-A | Resin composition and use thereof | 华为技术有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-117881677-A | Fused isoxazolyl compounds as KAT6Aw inhibitors | 奥瑞基尼肿瘤有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-112469720-B | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | 艾科思莱德制药公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-116514696-B | Ionizable lipids and uses thereof | 艾斯拓康医药科技(北京)有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-116981667-A | Heterocyclic inhibitors of EGFR and/or HER2 for cancer treatment | 蝎子疗法股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-11773075-B2 | Modulators of p97 AAA ATPase activity | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-10-03 | — | — | US | disclosed |
| US-5681959-A | DEPROTONATION OF A 2-AMINO-3-ALKYLPYRIDINE WITH AN ALKYLLITHIUM COMPOUND, THEN REACTION WITH AN AMIDE OR ESTER AND TREATMENT WITH A CONCENTRATED ACID FOR CYCLIZATION | MERCK, SHARP & DOHME LTD. (GB) | 1997-10-28 | — | — | US | disclosed |
| US-5637693-A | CEPHALOSPORIN ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1997-06-10 | — | — | US | disclosed |
| US-5362722-A | Antibiotics | ELI LILLY AND COMPANY (US) | 1994-11-08 | — | — | US | disclosed |
| US-5247073-A | Antibiotics for bactericides | ELI LILLY AND COMPANY (US) | 1993-09-21 | — | — | US | disclosed |
| EP-0495584-A2 | Cephalosporin compounds and their pharmaceutical compositions | ELI LILLY AND COMPANY (US) | 1992-07-22 | — | — | EP | disclosed |
| EP-0495585-A1 | Antibacterial agents | ELI LILLY AND COMPANY (US) | 1992-07-22 | — | — | EP | disclosed |
| US-5077287-A | Treating infectious diseases in man and animals | ELI LILLY AND COMPANY (US) | 1991-12-31 | — | — | US | disclosed |
| US-4751295-A | 7-(2-(5-AMINO-1,2,4-THIADIAZOL-3-YL)-2-OXYIMINOACETAMIDO)-3-(3 -(QUATERNARY AMMONIO)-1-PROPEN-1-YL)-3-CEPHEM-4-CARBOXYLATES | BRISTOL-MYERS COMPANY (US) | 1988-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773075-B2 | Modulators of p97 AAA ATPase activity | PSMG3, CDC37, AHSA1 | NAMPT 2491/4885RAB9A 853/4885NPC1 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.